Connection
Yuwen Zhu to Cell Line, Tumor
This is a "connection" page, showing publications Yuwen Zhu has written about Cell Line, Tumor.
|
|
Connection Strength |
|
 |
|
 |
|
0.389 |
|
|
|
-
Fujiwara Y, Torphy RJ, Sun Y, Miller EN, Ho F, Borcherding N, Wu T, Torres RM, Zhang W, Schulick RD, Zhu Y. The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun. 2021 10 06; 12(1):5857.
Score: 0.121
-
Fujiwara Y, Sun Y, Torphy RJ, He J, Yanaga K, Edil BH, Schulick RD, Zhu Y. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. Cancer Res. 2018 12 01; 78(23):6655-6665.
Score: 0.098
-
Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017 Oct; 66(10):1367-1375.
Score: 0.090
-
Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, Yao S, Bevers S, Edil BH. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016 Feb 08; 213(2):167-76.
Score: 0.081
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|